Routine use of zoledronic acid in early-stage breast cancer.

Published

Journal Article (Review)

Zoledronic acid, a potent nitrogen-containing bisphosphonate, plays a key role in preventing complications of bone metastases in metastatic breast cancer, but its affect on early-stage breast cancer has been unclear. The preclinical data supporting the anticancer effects of zoledronic acid are compelling and several recent clinical trials have suggested that it reduces breast cancer recurrence in certain patient subgroups. Given these anticancer effects and reasonable safety profile, this therapeutic option could be discussed with patients. This article focuses on the results of supporting preclinical and clinical data evaluating the role of zoledronic acid in adjuvant breast cancer therapy.

Full Text

Duke Authors

Cited Authors

  • Harnden, K; Blackwell, K

Published Date

  • April 2015

Published In

Volume / Issue

  • 13 / 4

Start / End Page

  • 480 - 486

PubMed ID

  • 25870382

Pubmed Central ID

  • 25870382

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Language

  • eng

Conference Location

  • United States